Navigation Links
GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients
Date:7/13/2009

ARLINGTON, Va., July 13 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on the Senate HELP Committee's vote on biogenerics legislation.

"While we are extremely disappointed that the Committee action could result in patients having little or no access to affordable biogenerics, we will continue to fight in the House to ensure that a true balance is achieved between innovation and competition. It is surprising that in the wake of the recent Federal Trade Commission report explicitly stating that 12 years of exclusivity would discourage innovation, the HELP Committee voted in favor of profits over patients. This unprecedented action strikes a huge blow to consumers at a time when many Americans are struggling to pay for the medicines they need.

"With generics saving the health care system $734 billion in the last decade, the House must now act to ensure that additional savings can be achieved by rejecting unnecessary and excessive years of market exclusivity for biopharmaceuticals. Over the last two years, we have dispelled the myths on the safety and efficacy of biogenerics that brand PhRMA and BIO tried to make to keep biogenerics from getting to consumers. It is now time to dispel the myth that double-digit years of exclusivity are needed to spark innovation. The White House already has the FDA working on creating a pathway and it has firmly stated that seven years of exclusivity is a good compromise. We must follow the course of the White House and Chairman Waxman and ensure that patients can truly access lifesaving biogeneric medicines in a timely manner.

"We hope that when the House Energy and Commerce Committee acts it follows the lead of its Chairman in approving a market exclusivity period that puts patients first. History has shown that a balance between innovation and competition can be achieved that benefits consumers and industry alike. Chairman Waxman knows this and we encourage him to continue to make patients the priority."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE Generic Pharmaceutical Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
3. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
4. International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive
5. Kaiser Permanente CEO Calls for Connected Health Care
6. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
7. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
8. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
9. Bauer Calls Taxpayer-Funded Embryonic Stem Cell Research A Tragedy
10. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
11. Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, today announced it has ... entered into a $5 million credit facility with ... the capital for general corporate purposes to further ... treatment of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
(Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... has further extended its industry leading Biochemistry Services specifically targeting the rapidly ... techniques and methods for the biochemical and biosimilar characterization , product-related ...
Breaking Biology Technology:
(Date:1/18/2017)... Md. , Jan. 18, 2017  In vitro ... respect to mergers and acquisitions (M&A), and Kalorama Information ... for such acquisitions have been shifting. Generally, uncertainty in ... and the U.S. has changed the acquisitions landscape. ... has resulted in companies buying partners outside of their ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
Breaking Biology News(10 mins):